<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SOC</title>
	<atom:link href="http://www.stockbloghub.com/tag/soc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BRCM) Broadcom Corporation &#8211; Trades at Discount to Industry P/E Ratio</title>
		<link>http://www.stockbloghub.com/2010/05/12/brcm-broadcom-corporation-trades-at-discount-to-industry-pe-ratio/36936</link>
		<comments>http://www.stockbloghub.com/2010/05/12/brcm-broadcom-corporation-trades-at-discount-to-industry-pe-ratio/36936#comments</comments>
		<pubDate>Wed, 12 May 2010 21:45:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Integrated Circuits]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[SOC]]></category>
		<category><![CDATA[Stoneleigh Partners Acquisition Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36936</guid>
		<description><![CDATA[Broadcom Corp. (BRCM) recently hit a new multi-year high on much better than expected Q1 results that saw revenue jump 71% from last year. Estimates are on the rise, helping to keep the valuation picture in check with a forward P/E of 18X. Company Description Broadcom Corp. designs and develops semiconductors for wired and wireless applications. The company sells its Systems-on-Chip (SOC) to a broad range of industries Incorporatedluding broadband, mobile devices and infrastructure. Broadcom was founded in 1991 and has a market cap of $18 billion. Broadcom&#8217;s business has rebounded sharply from it&#8217;s 2009 lows as both consumer and corporate spending have gained traction on a stronger global economy. This dynamic was on full display on April 27 when the company posted awesome Q1 results that easily beat expectations. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/12/brcm-broadcom-corporation-trades-at-discount-to-industry-pe-ratio/36936/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Pharmaceuticals Drug Meets Key Study Goals</title>
		<link>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216</link>
		<comments>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216#comments</comments>
		<pubDate>Fri, 18 Dec 2009 23:40:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RVR]]></category>
		<category><![CDATA[SOC]]></category>
		<category><![CDATA[Stoneleigh Partners Acquisition Corporation]]></category>
		<category><![CDATA[White River Capital Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23216</guid>
		<description><![CDATA[Anadys Pharmaceuticals Inc. (ANDS) announced that its lead candidate, ANA598, which is being developed for treating patients with hepatitis C virus (HCV) infections has met its key goals in a mid-stage study. The study saw HCV patients being treated with ANA598 in combination with pegylated interferon and ribavirin &#8211; the current standard of care (SOC) &#8211; at a 200 mg bid dosage level and analyzed at four weeks. The drug was generally well tolerated. No discontinuations because of serious adverse events were reported even though eight patients, seven mild and one moderate, developed rash in the interim analysis. The interim data from the four-week analysis revealed that 56% patients who received the HCV drug in combination with the SOC showed undetectable traces of the virus, Rapid Virological Response (RVR), at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

